HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
1. Fruquintinib and sintilimab showed significant PFS improvement in renal cancer. 2. Median PFS for the combination therapy was 22.2 months. 3. NDA for this combination therapy has been accepted for review in China. 4. Adverse events in the combination therapy group were higher than monotherapy. 5. Study results may reshape treatment strategies for advanced kidney cancer.